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Dear Sir:
Silent brain infarcts are associated with cognitive dysfunction 
similar to overt strokes in af (AF) patients.1 Brain magnetic res-
onance imaging (bMRI) is needed to detect silent infarcts and 
initiate secondary prevention, but is unfeasible in all patients. 
We therefore investigated the associations of biomarkers, clini-
cal variables and the CHA2DS2-VASc score with silent brain in-
farcts to non-invasively identify high-risk patients. 
The Swiss Atrial Fibrillation (Swiss-AF) cohort is a prospec-
tive, multicenter study, that enrolled patients with previously 
documented AF and age ≥65 years (subset aged 45 to 65 years 
was included).1 The study complies with the Declaration of 
Helsinki, the study protocol was approved by the local ethics 
committees (approval number 2014-067) and informed written 
consent was obtained from each participant. Of 2,415 enrolled 
patients, we excluded 479 (19.8%) with a history of stroke or 
transient ischemic attack (TIA) to analyze only silent brain in-
farcts, 658 (27.2%) without standardized bMRI and 381 
(15.8%) without complete biomarker assessment, leaving 1,140 
patients. Cognitive function was assessed by the Montreal 
Cognitive Assessment (MoCA) (maximum score 30 points, 
higher scores indicating better cognition, one point was added 
if formal education ≤12 years).2 A 12-lead electrocardiogram 
(ECG) was performed at enrolment. Details on biomarker selec-
tion are provided in the Supplementary material.3-12 Large 
non-cortical infarcts were defined as hyperintense lesions on 
fluid attenuated inversion recovery (FLAIR) >20 mm in diame-
ter on axial sections without cortical involvement. Cortical in-
farcts as hyperintense lesions of any size on FLAIR involving 
the cortex. Large non-cortical and any cortical infarct (LNCCIs) 
were combined into one category and chosen as the primary 
outcome as LNCCI were the only brain lesions independently 
associated with cognitive dysfunction.1 
Biomarkers and LNCCI volumes were log-transformed. To in-
vestigate associations of biomarkers with LNCCI presence and 
volume, we standardized (z-score) all biomarkers in crude, age/
sex-adjusted and multivariable (adjusted for prespecified vari-
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ables) models. To maximize the area under the curve (AUC) for 
diagnosing silent LNCCIs, a biomarker combination was select-
ed by backward selection from a model containing all biomark-
ers and the CHA2DS2-VASc score as a continuous variable. 
Similar backward selection was repeated for clinical variables 
and a combination of clinical variables and biomarkers. Clinical 
variables included sex, age, body mass index, active smoking, 
arterial hypertension, prior heart failure, diabetes, vascular dis-
ease, and presence of AF on a 12-lead ECG. We then compared 
the AUCs of the biomarkers, the CHA2DS2-VASc score, the clini-
Figure 1. (A) Separate logistic regression models for the relations of biomarker and large non-cortical and any cortical infarct (LNCCI). (B) Area under the 
curve (AUC) to diagnose LNCCI for different models. OR, odd ratio; CI, confidence interval; NT-proBNP, N-terminal pro-B-type natriuretic peptide; GDF-15, 
growth differentiation factor-15; IGFBP-7, insulin-like growth factor-binding protein-7; ESM-1, endothelial cell-specific molecule-1; hFABP-3, heart fat-


































































































AUC (95% CI) 0.666 (0.622; 0.710)
AUC (95% CI) 0.633 (0.589; 0.677)
AUC (95% CI) 0.662 (0.617; 0.706)
AUC (95% CI) 0.602 (0.558; 0.647)
A
Biomarkers Crude Age/sex adjusted Multivariable
OR (95% CI) OR (95% CI) OR (95% CI)
NT-proBNP 1.65 (1.37; 1.97) 1.51 (1.24; 1.84) 1.42 (1.16; 1.75)
GDF-15 1.51 (1.30; 1.77) 1.38 (1.16; 1.65) 1.38 (1.13; 1.69)
Osteopontin 1.52 (1.31; 1.76) 1.42 (1.20; 1.67) 1.36 (1.14; 1.62)
Hs-troponin T 1.51 (1.29; 1.76) 1.38 (1.16; 1.64) 1.34 (1.12; 1.61)
IGFBP-7 1.53 (1.31; 1.78) 1.39 (1.18; 1.66) 1.34 (1.12; 1.60)
ESM-1 1.37 (1.17; 1.16) 1.22 (1.02; 1.46) 1.26 (1.06; 1.49)
Cystatin C 1.42 (1.22; 1.65) 1.29 (1.09; 1.53) 1.26 (1.05; 1.50)
Interleukin-6 1.38 (1.17; 1.62) 1.27 (1.07; 1.51) 1.23 (1.02; 1.48)
Angiopoietin 1.4 (1.19; 1.65) 1.30 (1.09; 1.54) 1.22 (1.02; 1.46)
hFABP-3 1.34 (1.15; 1.56) 1.19 (1.02; 1.43) 1.16 (0.97; 1.40)
Creatinine 1.29 (1.11; 1.49) 1.18 (1.02; 1.38) 1.15 (0.97; 1.36)
Hs-CRP 1.12 (0.95; 1.31) 1.08 (0.91; 1.27) 1.05 (0.89; 1.25)
0.5 1.0 1.5 2.0 0.5 1.0 1.5 2.0 0.5 1.0 1.5 2.0
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cal variables, and their combinations. The final model with the 
highest AUC, a combination of biomarker and clinical variables, 
was internally validated based on 1,000 simulations using 
bootstrap with replacement. All statistical analyses were per-
formed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) 
or R version 3.5.1 (R Foundation for Statistical Computing, Vi-
enna, Austria) (registration-URL: http://www.clinicaltrials.gov; 
unique identifier: NCT02105844). 
Mean±standard deviation age was 72.1±8.7 years, 836 
(73.3%) patients were male and 445 (45.9%) had paroxysmal 
AF. LNCCI were present in 170 (14.9%) patients and median 
volume was 492 mm3 (interquartile range [IQR], 144 to 3,510). 
All biomarkers except for creatinine, high-sensitivity C-reactive 
protein, and heart fatty-acid-binding protein-3 (hFABP-3) were 
individually associated with present LNCCI (Figure 1A). Levels 
of hs-troponinT (β=0.33; 95% confidence interval [CI], 0.02 to 
0.64; P=0.04) and angiopoietin-2 (β=0.33; 95% CI, 0.03 to 
0.63; P=0.03) were also associated with LNCCI volumes. 
AUCs for all different models are shown in Figure 1B (details 
in Supplementary material). The combination of hs-troponinT, 
osteopontin, hFABP-3, vascular disease, and AF on the ECG had 
the highest AUC of 0.679 (95% CI, 0.636 to 0.722) for LNCCI 
and was therefore selected as the final model. Individual odds 
ratios (ORs) were 1.31 (95% CI, 1.06 to 1.62; P=0.01 for hs-tro-
poninT), 1.38 (95% CI, 1.12 to 1.70; P=0.002 for osteopontin), 
0.82 (95% CI, 0.65 to 1.04; P=0.10 for hFABP-3), 1.76 (95% CI, 
1.24 to 2.51; P=0.002 for vascular disease), and 1.64 (95% CI, 
1.16 to 2.32; P=0.005 for AF on the ECG). Internal validation 
showed an AUC of 0.662 (IQR, 0.643 to 0.682). 
The AUC for vascular disease and AF on the ECG alone was 
0.633 (95% CI, 0.589 to 0.677; P=0.001 compared to the final 
model) and their respective ORs were 2.10 (95% CI, 1.50 to 
2.96; P<0.0001) and 1.95 (95% CI, 1.40 to 2.72; P<0.0001). 
The biomarker combination of hs-troponinT, N-terminal pro-B-
type natriuretic peptide (NT-proBNP), osteopontin, and 
hFABP-3 had an AUC of 0.662 (95% CI, 0.617 to 0.706; P=0.16 
compared to the final model), without any significant improve-
ment by adding the CHA2DS2-VASc score. Individual ORs were 
1.33 (95% CI, 1.07 to 1.64; P=0.009 for hs-troponinT), 1.34 
(95% CI, 1.08 to 1.66; P=0.008 for NT-proBNP), 1.34 (95% CI, 
1.08 to 1.66; P=0.007 for osteopontin), and 0.80 (95% CI, 0.63 
to 1.02; P=0.07 for hFABP-3). The AUC and OR for the 
CHA2DS2-VASc score alone were 0.602 (95% CI, 0.558 to 
0.647; P=0.0002 compared to the final model) and 1.28 (95% 
CI, 1.14 to 1.44; P<0.0001), respectively. 
Risk quartiles based on the final model showed increasing 
LNCCI prevalence from 7.4%, 8.8%; 16.8% to 26.7% and de-
creasing MoCA scores from 26.3, 26.3; 25.3 to 24.8 points over 
increasing quartiles (P<0.0001 for both). 
We comprehensively assessed the associations of clinical pa-
rameters, biomarkers, and the CHA2DS2-VASc score with silent 
brain infarcts. Approximately one out of four AF patients in the 
highest risk quartile, based on the final model, had a silent 
brain infarct. Thus, our risk model identifies a high-risk popula-
tion for bMRI screening. Once silent brain lesions are con-
firmed, these patients might benefit from initiation or adjust-
ment of anticoagulation, reduction in AF-burden,13 and treat-
ment of traditional stroke risk factors.14 Randomized trials are 
needed to establish the impact of those interventions on cog-
nitive decline related to silent infarcts. Strengths of our study 
include the large sample size, a wide biomarker array and de-
tailed patient characterization. Limitations are unclear gener-
alizability to patients with transient AF forms, cardiac devices 
and a history of stroke/TIA. 
In conclusion, the combination of hs-troponinT, osteopontin, 
hFABP-3, vascular disease, and AF on the ECG had the highest 
discriminatory ability to diagnose clinically silent LNCCIs.
Supplementary materials
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2021.02068.
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Appendix 1. Swiss-AF investigators
University Hospital Basel/Basel University: Stefanie Aeschbach-
er, Steffen Blum, Leo Bonati, Peter Hämmerle, Philipp Krisai, 
Christine Meyer-Zürn, Pascal Meyre, Andreas U. Monsch, Chris-
tian Müller, Christiane Pudenz, Philipp Reddiess, Javier Ruperti 
Repilado, Aleksandra Schweizer, Anne Springer, Fabienne Stein-
er, Christian Sticherling, Thomas Szucs, Gian Voellmin, Leon 
Zwimpfer; Local Principal Investigator (Michael Kühne); Princi-
pal Investigators (Stefan Osswald, David Conen)
University Hospital Bern: Faculty (Drahomir Aujesky, Urs 
Fischer, Juerg Fuhrer, Laurent Roten, Simon Jung, Heinrich 
Mattle); Research fellows (Luise Adam, Carole Elodie Aubert, 
Martin Feller, Claudio Schneider, Axel Loewe, Elisavet Mout-
zouri); Study nurses (Tanja Flückiger, Cindy Groen, Nathalie 
Schwab); Local Principal Investigator (Nicolas Rodondi)
Stadtspital Triemli Zurich: Christopher Beynon, Roger Dillier, 
Franz Eberli, Simone Fontana, Christine Franzini, Isabel Juchli, 
Claudia Liedtke, Jacqueline Nadler, Thayze Obst, Noreen Tynan, 
Xiaoye Schneider, Katrin Studerus, Dominik Weishaupt; Local 
Principal Investigator (Andreas Müller)
Kantonspital Baden: Silke Kuest, Karin Scheuch, Denise His-
chier, Nicole Bonetti, Corina Bello, Henriette Isberg, Alexandra 
Grau, Jonas Villinger, Mary-Monica Papaux, Eva Laube, Philipp 
Baumgartner, Mark Filipovic, Marcel Frick, Stefanie Leuenberg-
er; Local Principal Investigator (Jürg H. Beer)
Cardiocentro Lugano: Angelo Auricchio, Adriana Anesini, 
Cristina Camporini, Giulio Conte, Maria Luce Caputo, Francois 
Regoli, Tiziano Moccetti; Local Principal Investigator (Tiziano 
Moccetti) 
Kantonsspital St. Gallen: Roman Brenner, David Altmann, 
Manuela Forrer, Michaela Gemperle; Local Principal Investiga-
tor (Peter Ammann)
Hôpital Cantonal Fribourg: Mathieu Firmann, Sandrine Fou-
cras; Local Principal Investigator (Daniel Hayoz)
Luzerner Kantonsspital: Benjamin Berte, Andrea Kaeppeli, 
Myriam Roth, Brigitta Mehmann, Markus Pfeiffer, Ian Russi, Kai 
Schmidt, Vanessa Weberndoerfer, Mabelle Young, Melanie 
Zbinden; Local Principal Investigator (Richard Kobza)
Ente Ospedaliero Cantonale Lugano: Luisa Vicari, Jane Fran-
gi-Kultalahti, Tatiana Terrot; Local Principal Investigator (Gior-
gio Moschovitis)
University Hospital Geneva: Georg Ehret, Hervé Gallet, Elise 
Guillermet, Francois Lazeyras, Karl-Olof Lovblad, Patrick Perret, 
Cheryl Teres; Local Principal Investigator (Dipen Shah)
University Hospital Lausanne: Nathalie Lauriers, Marie Méan, 
Sandrine Salzmann; Local Principal Investigator (Jürg Schläpfer)
Bürgerspital Solothurn: Nisha Arenja, Andrea Grêt, Sandra 
Vitelli; Local Principal Investigator (Jan Novak)
Ente Ospedaliero Cantonale Bellinzona: Jane Frangi, Augusto 
Gallino; Local Principal Investigator (Marcello Di Valentino)
St. Anna Spital Luzern: Renate Schoenenberger-Berzins
University of Zurich/University Hospital Zurich: Fabienne Wi-
tassek, Matthias Schwenkglenks, Christoph Stippich
Medical Image Analysis Center AG Basel: Ernst-Wilhelm Ra-
due, Tim Sinnecker, Jens Würfel
Clinical Trial Unit Basel: Pascal Benkert, Thomas Fabbro, Pat-
rick Simon, Michael Coslovsky
Schiller AG Baar: Ramun Schmid




Biomarkers were selected based on biological plausibility, prior 
literature and availability. We included biomarkers of inflam-
mation and oxidative stress,3-5 myocardial injury and strain,5-8 
vascular damage,9,10 renal dysfunction,11 and cerebral damage.12 
C-reactive protein (CRP) and interleukin-6 were both posi-
tively associated with an inflammatory, prothrombotic state 
and CRP was additionally shown to directly related to stroke 
risk.3,4 Growth differentiation factor-15 was associated with 
stroke-related death among with troponinT and N-terminal 
prohormone of brain natriuretic peptide (NT-proBNP).5,6 More-
over, NT-proBNP is released into the serum after acute isch-
aemic stroke, as are heart-fatty acid binding proteins (hFABPs).8 
As a marker for left atrial dilatation, insulin-like growth fac-
tor-binding protein-7 (IGFBP-7) was shown to be positively as-
sociated with left atrial size.7 Renal markers were included, as 
renal insufficiency is known to influence the efficacy of antico-
agulants in atrial fibrillation patients.11 As vascular markers, 
angiopoietin-2 was shown to be upregulated after cerebral ar-
tery occlusion in an experimental model and endothelial 
cell-specific molecule-1 (ESM-1) plays a crucial role in vascular 
permeability after ischemic stroke.9,10 Osteopontin acts as a di-
rect marker of cerebral damage after ischemic stroke and was 
therefore also included in our analyses.12 
Detailed description for Figure 1B
Receiver operating curves are displayed, showing the accuracy 
of the models to diagnose large non-cortical and cortical in-
farcts. Final model (area under the curve [AUC], 0.679; 95% 
confidence interval [CI], 0.636 to 0.722) includes hs-troponin T, 
osteopontin, heart fatty-acid binding protein 3, vascular dis-
ease, and atrial fibrillation on the electrocardiogram (ECG). 
Biomarker model (AUC, 0.662; 95% CI, 0.617 to 0.706; P=0.16 
compared to the final model) includes hs-troponin T, NT-proB-
NP, heart fatty-acid binding protein 3, and osteopontin. The 
addition of the CHA2DS2-VASc score to the biomarker combi-
nation did not improve the AUC of 0.666 (95% CI, 0.622 to 
0.710; P=0.29 compared to the final model). Clinical variables 
(AUC, 0.633; 95% CI, 0.589 to 0.677; P=0.001 compared to the 
final model) include vascular disease and atrial fibrillation on 
the ECG. The CHA2DS2-VASc score alone had an AUC of 0.602 
(95% CI, 0.558 to 0.647; P=0.0002 compared to the final mod-
el).
